Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Terri A. Addona"'
Autor:
Asaf Poran, Dewi Harjanto, Matthew Malloy, Christina M. Arieta, Daniel A. Rothenberg, Divya Lenkala, Marit M. van Buuren, Terri A. Addona, Michael S. Rooney, Lakshmi Srinivasan, Richard B. Gaynor
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Abstract Background The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/9f61d50420b745d5900a6a515483100a
Autor:
Dos D. Sarbassov, David M. Sabatini, Mark A. Magnuson, Steven A. Carr, Hasmik Keshishian, Terri A. Addona, Timothy R. Peterson, Nitin K. Agarwal, Tattym Shaikenov, Chien-Hung Chen, Delphine Boulbes
Supplementary Data from Rictor Phosphorylation on the Thr-1135 Site Does Not Require Mammalian Target of Rapamycin Complex 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23659829f88e380f269558fffa09aa25
https://doi.org/10.1158/1541-7786.22519155.v1
https://doi.org/10.1158/1541-7786.22519155.v1
Autor:
Dos D. Sarbassov, David M. Sabatini, Mark A. Magnuson, Steven A. Carr, Hasmik Keshishian, Terri A. Addona, Timothy R. Peterson, Nitin K. Agarwal, Tattym Shaikenov, Chien-Hung Chen, Delphine Boulbes
In animal cells, growth factors coordinate cell proliferation and survival by regulating the phosphoinositide 3-kinase/Akt signaling pathway. Deregulation of this signaling pathway is common in a variety of human cancers. The PI3K-dependent signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5107286051fc5b6ea843edffc7b7045
https://doi.org/10.1158/1541-7786.c.6542322.v1
https://doi.org/10.1158/1541-7786.c.6542322.v1
Autor:
Christina M. Arieta, Richard B. Gaynor, Marit M. van Buuren, Daniel A. Rothenberg, Dewi Harjanto, Michael S. Rooney, Divya Lenkala, Lakshmi Srinivasan, Asaf Poran, Terri A. Addona, Matthew Malloy
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Genome Medicine
Genome Medicine
BackgroundThe ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.MethodsWe
Autor:
Jared L. Dietze, Daniel A. Rothenberg, Terri A. Addona, Antoine Boudot, Jessica Kohler, Jennifer G. Abelin, Vikram R. Juneja, Paul J. Turcott, Brandon P. Conn, Marit M. van Buuren, Scott P. Goulding, Christopher D. McGann, Richard B. Gaynor, John R. Srouji, Kendra C. Foley, Jae Won Choi, Michael S. Rooney, Divya Lenkala
Publikováno v:
Cell Reports Methods. 1:100084
Summary Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell res
Autor:
Terri A. Addona, Christina M. Arieta, Richard B. Gaynor, Dewi Harjanto, Yusuf Nasrullah, Dominik Barthelme, Jeff Hammerbacher, Matthew Malloy, Edward F. Fritsch, Rob C. Oslund, Prerna Suri, Asaf Poran, Joel Greshock, Christopher D. McGann, Daniel A. Rothenberg, Sagar Chhangawala, Scott P. Goulding, Alex Rubinsteyn, Tyler Colson, Gibran Nasir, Amanda L. Creech, Ying S. Ting, Michael S. Rooney, Diana Velez, Jennifer G. Abelin, Lia R. Serrano
Publikováno v:
Immunity. 51(4)
Summary Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), h
Autor:
Vikram R. Juneja, Terri A. Addona, John Srouji, Jae Won Choi, Michael S. Rooney, Brandon P. Conn, Paul J. Turcott, Christopher D. McGann, Jennifer G. Abelin, Richard B. Gaynor, Antoine Boudot, Marit M. van Buuren, Scott P. Goulding, Jessica Kohler, Divya Lenkala, Daniel A. Rothenberg, Jared L. Dietze
Publikováno v:
Cancer Research. 80:PO-015
Response rates to immunotherapies in pancreatic ductal adenocarcinoma (PDAC) patients are low. However, cases with long-term survival have been correlated with both T cell infiltration and quality of neoantigens (i.e., epitopes from mutations present
Autor:
Terri A. Addona, Asaf Poran, Matthew Malloy, Michael S. Rooney, Daniel A. Rothenberg, Divya Lenkala, Lakshmi Srinivasan, Dewi Harjanto, Christina M. Arieta, Richard B. Gaynor, Marit M. van Buuren
Publikováno v:
Clinical Cancer Research. 26:S03-02
The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Consistent with observations for the closely related SARS-CoV, early reports identify a protective role for both humora
Autor:
Rob C. Oslund, Dewi Harjanto, Jennifer G. Abelin, Jeff Hammerbacher, Yusuf Nasrullah, Sagar Chhangawala, Lia R. Serrano, Alex Rubinsteyn, Gibbs Nasir, Amanda L. Creech, Ying S. Ting, Christopher D. McGann, Asaf Poran, Edward F. Fritsch, Michael S. Rooney, Tyler Colson, Dominik Barthelme, Daniel A. Rothenberg, Scott P. Goulding, Prerna Suri, Terri A. Addona, Matthew Malloy, Christina M. Arieta, Richard B. Gaynor, Diana Velez
Publikováno v:
Cancer Immunology Research. 8:B23-B23
While tumor-reactive CD4+ T cells have been associated with effective immunotherapy responses, accurate prediction of MHC class II-restricted ligands remains a challenge, limiting our ability to harness CD4+ immunity for cancer therapy. To this end,
Autor:
Amanda L. Creech, Ying S. Ting, Scott P. Goulding, John F.K. Sauld, Terri A. Addona, Dominik Barthelme, Jennifer G. Abelin, Michael S. Rooney
Publikováno v:
Proteomics
A challenge in developing personalized cancer immunotherapies is the prediction of putative cancer‐specific antigens. Currently, predictive algorithms are used to infer binding of peptides to human leukocyte antigen (HLA) heterodimers to aid in the